Table 1. Baseline demographics and clinical characteristics.
| Characteristic | Patiromer 16.8 g/day, N=25 |
|---|---|
| Age, years—mean (s.d.) | 58.7 (12.3) |
| Male—No. (%) | 15 (60) |
| Caucasian—No. (%) | 25 (100) |
| Body mass index, kg/m2—mean (s.d.) | 27.9 (3.9) |
| Type II diabetes mellitus—No. (%) | 15 (60) |
| Hypertension—No. (%) | 25 (100) |
| History of MI—No. (%) | 4 (16) |
| History of heart failure—No. (%) | 7 (28) |
| Duration of CKD, years—mean (s.d.) | 4.49 (4) |
| eGFR, ml/min per 1.73 m2—mean (s.d.) | 34.8 (20.7) |
| CKD stagea—No. (%) | |
| ⩾90 ml/min per 1.73 m2 | 1 (4) |
| 60–89 ml/min per 1.73 m2 | 2 (8) |
| 30–59 ml/min per 1.73 m2 | 9 (36) |
| 15–29 ml/min per 1.73 m2 | 11 (44) |
| <15 ml/min per 1.73 m2 | 2 (8) |
| Serum potassium,b mEq/l—mean (s.d.) | 5.93 (0.18) |
| Serum potassium >6.0 mEq/l—No. (%) | 8 (32) |
| On a RAASi—No. (%) | 25 (100) |
| Diuretic—No. (%) | 11 (44) |
Abbreviations: CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; MI, myocardial infarction; RAASi, renin–angiotensin–aldosterone system inhibitor; s.d., standard deviation.
a
Stage 1 (normal): ⩾90 ml/min per 1.73 m2; Stage 2 (mild): 60–89 ml/min per 1.73 m2; Stage 3 (moderate): 30–59 ml/min per 1.73 m2; Stage 4 (severe): 15–29 ml/min per 1.73 m2; Stage 5 (end-stage): <15 ml/min per 1.73 m2.
b
Average of two central laboratory serum potassium values from samples collected at hour −1 and 0 on treatment day 1.